IL285813A - antigenic proteins that bind bmca - Google Patents
antigenic proteins that bind bmcaInfo
- Publication number
- IL285813A IL285813A IL285813A IL28581321A IL285813A IL 285813 A IL285813 A IL 285813A IL 285813 A IL285813 A IL 285813A IL 28581321 A IL28581321 A IL 28581321A IL 285813 A IL285813 A IL 285813A
- Authority
- IL
- Israel
- Prior art keywords
- antigen binding
- binding proteins
- bind bcma
- bcma
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810771P | 2019-02-26 | 2019-02-26 | |
| US201962811431P | 2019-02-27 | 2019-02-27 | |
| PCT/US2020/019763 WO2020176549A1 (en) | 2019-02-26 | 2020-02-25 | Antigen binding proteins that bind bcma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL285813A true IL285813A (en) | 2021-10-31 |
Family
ID=72238662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL285813A IL285813A (en) | 2019-02-26 | 2021-08-23 | antigenic proteins that bind bmca |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210388097A1 (https=) |
| EP (1) | EP3930852A4 (https=) |
| JP (1) | JP7554759B2 (https=) |
| KR (1) | KR20210133261A (https=) |
| CN (1) | CN113874082B (https=) |
| AU (1) | AU2020228367A1 (https=) |
| BR (1) | BR112021016791A2 (https=) |
| CA (1) | CA3130765A1 (https=) |
| IL (1) | IL285813A (https=) |
| MX (1) | MX2021010281A (https=) |
| SG (1) | SG11202109163YA (https=) |
| WO (1) | WO2020176549A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022546577A (ja) * | 2019-09-05 | 2022-11-04 | ソレント・セラピューティクス・インコーポレイテッド | Ｂｃｍａと結合する二量体抗原受容体（ｄａｒ） |
| MX2023007901A (es) | 2020-12-31 | 2023-07-11 | Sanofi Sa | Acopladores de celulas asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123. |
| US20240181073A1 (en) | 2021-03-03 | 2024-06-06 | Sorrento Therapeutics, Inc. | Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody |
| IL317227A (en) | 2022-05-27 | 2025-01-01 | Sanofi Sa | Combined natural killer (NK) cells bind to NKP46 and BCMA variants with FC engineering |
| US20240117062A1 (en) * | 2022-05-27 | 2024-04-11 | Sanofi | Anti-bcma antibodies |
| CN119841951B (zh) * | 2024-12-25 | 2025-10-14 | 厦门大学附属第一医院(厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所) | 一种抗bcma抗体或其抗原结合片段及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6342220B1 (en) * | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| GB9908533D0 (en) * | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
| US7214786B2 (en) * | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| WO2005016111A2 (en) * | 2003-08-08 | 2005-02-24 | Abgenix, Inc. | Antibodies directed to parathyroid hormone (pth) and uses thereof |
| ES2650224T3 (es) * | 2007-08-21 | 2018-01-17 | Amgen, Inc. | Proteínas de unión al antígeno C-FMS humano |
| EA201590877A1 (ru) * | 2012-11-13 | 2015-09-30 | Ридженерон Фармасьютикалз, Инк. | Антитела к прокинетициновым рецепторам (prokr) их применение |
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| TW201632559A (zh) * | 2015-02-22 | 2016-09-16 | 索倫多醫療公司 | 結合ｃｄ１３７之抗體治療劑 |
| PL3988117T3 (pl) * | 2015-04-13 | 2025-03-10 | Pfizer Inc. | Przeciwciała terapeutyczne i ich zastosowania |
| US10072088B2 (en) * | 2015-08-17 | 2018-09-11 | Janssen Pharmaceutica, Nv | Anti-BCMA antibodies and uses thereof |
| US20170233484A1 (en) * | 2016-02-17 | 2017-08-17 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
| US10988546B2 (en) * | 2017-08-01 | 2021-04-27 | Medimmune, Llc | BCMA monoclonal antibody-drug conjugate |
| US20200224160A1 (en) * | 2018-02-27 | 2020-07-16 | Sorrento Therapeutics, Inc. | Process for dna integration using rna-guided endonucleases |
| CN109265550B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Bcma抗体、嵌合抗原受体和药物 |
| JP2022546577A (ja) * | 2019-09-05 | 2022-11-04 | ソレント・セラピューティクス・インコーポレイテッド | Ｂｃｍａと結合する二量体抗原受容体（ｄａｒ） |
-
2020
- 2020-02-25 SG SG11202109163YA patent/SG11202109163YA/en unknown
- 2020-02-25 WO PCT/US2020/019763 patent/WO2020176549A1/en not_active Ceased
- 2020-02-25 JP JP2021549630A patent/JP7554759B2/ja active Active
- 2020-02-25 MX MX2021010281A patent/MX2021010281A/es unknown
- 2020-02-25 BR BR112021016791A patent/BR112021016791A2/pt not_active IP Right Cessation
- 2020-02-25 AU AU2020228367A patent/AU2020228367A1/en not_active Abandoned
- 2020-02-25 CN CN202080031584.2A patent/CN113874082B/zh not_active Expired - Fee Related
- 2020-02-25 EP EP20763127.6A patent/EP3930852A4/en not_active Withdrawn
- 2020-02-25 KR KR1020217030843A patent/KR20210133261A/ko not_active Withdrawn
- 2020-02-25 CA CA3130765A patent/CA3130765A1/en active Pending
-
2021
- 2021-08-23 IL IL285813A patent/IL285813A/en unknown
- 2021-08-25 US US17/412,089 patent/US20210388097A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3930852A4 (en) | 2022-12-28 |
| BR112021016791A2 (pt) | 2021-11-16 |
| EP3930852A1 (en) | 2022-01-05 |
| SG11202109163YA (en) | 2021-09-29 |
| JP7554759B2 (ja) | 2024-09-20 |
| MX2021010281A (es) | 2021-09-23 |
| CA3130765A1 (en) | 2020-09-03 |
| KR20210133261A (ko) | 2021-11-05 |
| US20210388097A1 (en) | 2021-12-16 |
| CN113874082A (zh) | 2021-12-31 |
| AU2020228367A1 (en) | 2021-10-14 |
| JP2022521956A (ja) | 2022-04-13 |
| CN113874082B (zh) | 2024-12-06 |
| WO2020176549A1 (en) | 2020-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290268A (en) | Antigen binding proteins that specifically bind mage-a | |
| IL260846B (en) | Antigen binding proteins that bind pd-l1 | |
| IL285813A (en) | antigenic proteins that bind bmca | |
| IL277848A (en) | HER2-targeting antigen-binding molecules containing 4-1BBL | |
| IL273886B (en) | B-cell maturation antigen-binding proteins | |
| IL263083A (en) | single chain variable segment cd3 binding proteins | |
| ZA201701912B (en) | Antigen binding proteins that bind cxcr5 | |
| AU2020243430A1 (en) | Antigen binding proteins | |
| GB201802338D0 (en) | Antigen binding proteins | |
| IL289145A (en) | il1rap binding proteins | |
| IL281351A (en) | Enhanced anti-FLT3 antigen binding proteins | |
| GB201919294D0 (en) | Antibodies or binding proteins | |
| EP3131574A4 (en) | Antigen binding proteins that bind wisp1 | |
| IL304317A (en) | tgf–beta–rii binding proteins | |
| ZA201701941B (en) | Antigen binding proteins that bind cxcr3 | |
| GB201820446D0 (en) | Antigen binding molecules that bind light | |
| IL291364A (en) | Antigen binding proteins | |
| ZA201906821B (en) | Anti-jagged1 antigen binding proteins | |
| IL287158A (en) | A multi-specific antigen for binding protein complexes | |
| GB201614627D0 (en) | Antigen binding proteins | |
| GB201804531D0 (en) | Antigen binding proteins | |
| HK40080931A (en) | Anti-tirc7 antigen binding proteins | |
| HK40069000A (en) | Antigen binding proteins | |
| GB201919286D0 (en) | Binding proteins | |
| GB201911188D0 (en) | Antigen binding molecules that bind BDCA-2 |